SYRE vs. RNA, ACLX, OGN, ZLAB, RARE, SWTX, AKRO, ALVO, RYTM, and MRUS
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Avidity Biosciences (RNA), Arcellx (ACLX), Organon & Co. (OGN), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), Alvotech (ALVO), Rhythm Pharmaceuticals (RYTM), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry.
Spyre Therapeutics vs.
Avidity Biosciences (NASDAQ:RNA) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.
Avidity Biosciences currently has a consensus target price of $66.69, suggesting a potential upside of 104.83%. Spyre Therapeutics has a consensus target price of $50.33, suggesting a potential upside of 184.53%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spyre Therapeutics is more favorable than Avidity Biosciences.
Avidity Biosciences has higher revenue and earnings than Spyre Therapeutics. Avidity Biosciences is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
80.4% of Spyre Therapeutics shares are owned by institutional investors. 3.7% of Avidity Biosciences shares are owned by company insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Spyre Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,772.45%. Avidity Biosciences' return on equity of -27.66% beat Spyre Therapeutics' return on equity.
In the previous week, Avidity Biosciences had 9 more articles in the media than Spyre Therapeutics. MarketBeat recorded 20 mentions for Avidity Biosciences and 11 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.78 beat Avidity Biosciences' score of 0.71 indicating that Spyre Therapeutics is being referred to more favorably in the news media.
Avidity Biosciences has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.98, suggesting that its share price is 198% more volatile than the S&P 500.
Avidity Biosciences received 148 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 69.01% of users gave Avidity Biosciences an outperform vote.
Summary
Spyre Therapeutics beats Avidity Biosciences on 11 of the 19 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SYRE) was last updated on 3/28/2025 by MarketBeat.com Staff
